Shen'ge Formula Protects Cardiac Function in Rats with Pressure Overload-Induced Heart Failure
Boyong Qiu,Siyu Qiao,Xiujuan Shi,Lin Shen,Bing Deng,Zilin Ma,Duan Zhou,Yihong Wei
DOI: https://doi.org/10.2147/dddt.s451720
IF: 4.3188
2024-05-30
Drug Design Development and Therapy
Abstract:Boyong Qiu, 1, 2, &ast Siyu Qiao, 2, &ast Xiujuan Shi, 2 Lin Shen, 2 Bing Deng, 2 Zilin Ma, 2 Duan Zhou, 2 Yihong Wei 2 1 Heart Center/National Regional (Traditional Chinese Medicine) Cardiovascular Diagnosis and Treatment Center, The First Affiliated Hospital of Henan University of CM, Zhengzhou, Henan, People's Republic of China; 2 Cardiovascular Department, Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yihong Wei; Duan Zhou, Email ; Background: In China, Shen'ge formula (SGF), a Traditional Chinese Medicine blend crafted from ginseng and gecko, holds a revered place in the treatment of cardiovascular diseases. However, despite its prevalent use, the precise cardioprotective mechanisms of SGF remain largely uncharted. This study aims to fill this gap by delving deeper into SGF's therapeutic potential and underlying action mechanism, thus giving its traditional use a solid scientific grounding. Methods: In this study, rats were subjected to abdominal aortic constriction (AAC) to generate pressure overload. Following AAC, we administered SGF and bisoprolol intragastrically at specified doses for two distinct durations: 8 and 24 weeks. The cardiac function post-treatment was thoroughly analyzed using echocardiography and histological examinations, offering insights into SGF's influence on vital cardiovascular metrics, and signaling pathways central to cardiac health. Results: SGF exhibited promising results, significantly enhanced cardiac functions over both 8 and 24-week periods, evidenced by improved ejection fraction and fractional shortening while moderating left ventricular parameters. Noteworthy was SGF's role in the significant mitigation of myocardial hypertrophy and in fostering the expression of vital proteins essential for heart health by the 24-week mark. This intervention markedly altered the dynamics of the Akt/HIF-1α/p53 pathway, inhibiting detrimental processes while promoting protective mechanisms. Conclusion: Our research casts SGF in a promising light as a cardioprotective agent in heart failure conditions induced by pressure overload in rats. Central to this protective shield is the modulation of the Akt/HIF-1α/p53 pathway, pointing to a therapeutic trajectory that leverages HIF-1α promotion and p53 nuclear transport inhibition. Keywords: Shen'ge formula, heart failure, hypertrophy, apoptosis, angiogenesis Graphical Heart failure (HF) is a worldwide disease with high morbidity, rehospitalization, and mortality. Between 2013 and 2016, there were approximately 6.2 million HF patients ≥20 years of age in the USA. 1 The ESC-HF pilot study showed that the annual all-cause mortality rates were 17 and 7%, in hospitalized and stable HF patients, respectively, with corresponding annual hospitalization rates of 44 and 32%, respectively. 2 In China, approximately 13.7 million patients aged ≥35 years have HF, accounting for an incidence of approximately 1.3%. 3 Consequently, there is an urgent need to identify cardioprotective medicines for HF. Myocardial hypertrophy and angiogenesis play essential roles in maintaining cardiac homeostasis. Pathological hypertrophy occurring in HF is accompanied by angiogenic dysfunction, which in turn leads to further heart remodeling. 4,5 Studies have shown that effective inhibition of myocardial pathological hypertrophy and promotion of angiogenesis will help improve ventricular remodeling. 6,7 Apoptosis also plays a key role in the complex mechanisms of HF. The inhibition of apoptotic pathways can improve left ventricular remodeling in the progression of HF, 8 and the apoptotic protein p53 plays an essential role in this process. 9 p53 cannot only regulate caspase 3, Bax, and Bcl-2 to regulate apoptosis, 10 but is also closely related to myocardial apoptosis, hypertrophy, and angiogenesis in the progression of HF. 11,12 Shen'ge formula (SGF), a traditional Chinese medicine (TCM) formula consisting of ginseng and gecko in a 3:1 weight ratio, has a long clinical application history of more than 700 years in China. We found SGF effective in HF in our previous clinical studies, including ameliorating patients clinical symptoms, 13 strengthen cardiac systolic function, 14 and inhibiting brain natriuretic peptide or N-terminal pro B type natriuretic peptide. 15 Another previous study indicated that Gu Ben Pei Yuan San, another TCM formula containing ginseng, g -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal